ALIVUS · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 42/100 — Quality 52 · Valuation 20 · Momentum 57
| Share price | ₹1,132.30 |
| Market cap | ₹14,239 Cr |
| P/E ratio | 24.9 |
| P/B ratio | 4.3 |
| ROCE | 21.8% |
| Dividend yield | 0.43% |
| Book value | ₹271.02 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,552 Cr | ₹564 Cr | 28.3% |
| 2025 | ₹2,387 Cr | ₹486 Cr | 26.1% |
| 2024 | ₹2,185 Cr | ₹471 Cr | 28.5% |
| 2023 | ₹2,048 Cr | ₹467 Cr | 29.3% |
| 2022 | — | — | — |
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, res